PERCEPTIVE INFORMATICS NAMED WINNER IN THE EUROPEAN OUTSOURCING AWARDS--RECOGNIZED FOR ITS TRULY INTEGRATED ECLINICAL SOLUTION
Boston, MA, October 29, 2009 – Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), announced today that it has been named the winner of the Best e-Business/IT Strategy Category in The European Outsourcing Awards 2009. The winning entry from Perceptive Informatics titled “Gaining a Complete Trial Picture to Make More Effective Decisions in Real-Time: Realizing Key Benefits of a Truly Integrated eClinical Solution” focused on a customer’s success story using Perceptive’s eClinical Suite.
The award was presented to Perceptive Informatics at The European Outsourcing Awards 2009 Gala, held on October 14, 2009 in Madrid, Spain. The European Outsourcing Awards are designed to recognize new and significant developments in contract services and reward companies for their outstanding contributions and achievements. The awards were created to celebrate excellence in a number of areas across the biopharmaceutical industry, including technology.
According to Kevin Robinson, Ph.D., head of The European Outsourcing Awards judging panel and Editor of Pharma Magazine, “The European Outsourcing Award for the Best e-Business/IT Strategy, which was evaluated by an independent panel of judges, recognizes the leadership role Perceptive Informatics has established in the area of eClinical technologies. Perceptive Informatics has demonstrated its excellence based on effectively using IT to create a significant, exploitable competitive and operational advantage. This award recognizes Perceptive for its well thought-through and executed strategy, addressing not only the deployment of technology but also its effective uptake by users.”
“Perceptive Informatics is honored to be chosen by the judges as the winner of the Best e-Business/IT Strategy Category in The European Outsourcing Awards,” said Steve Kent, President, Perceptive Informatics, a PAREXEL Company. “We have addressed the opportunity to maximally leverage technology through our eClinical Suite, which we believe provides customers with the industry’s most integrated solution. Perceptive is committed to continuing to lead innovation, developing the next generation of technologies that are aligned to accelerate clinical development.”
The eClinical Suite from Perceptive Informatics represents a new level of integration and a dramatic shift in the way technologies can be used to streamline workflow while facilitating effective trial management. Providing interoperability among systems, including the IMPACT® Clinical Trial Management System (CTMS), the DataLabs® EDC solution, and the ClinPhone® Randomization and Trial Supply Management (RTSM) technologies, the eClinical Suite supports real-time data interchange and enables diverse applications to work synergistically. For more information about Perceptive’s eClinical Suite, visit http://www.perceptive.com/Solutions/eClinical-Suite.html.
# # #
Note: Perceptive’s Randomization and Trial Supply Management (RTSM) solutions incorporate functionality that is often referenced as Interactive Voice and Web Response Systems (IVRS/IWRS).
About Perceptive Informatics
Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. The Perceptive Informatics industry-leading eClinical product portfolio is built on advanced technology that benefits from extensive medical and clinical expertise as well as a deep understanding of the regulatory environment. The portfolio includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). For more information about the integrated solutions in Perceptive’s eClinical Suite visit: www.perceptive.com.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 52 countries around the world, and has over 9,130 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended June 30, 2009 as filed with the SEC on August 28, 2009, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.